In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Four Firms Vie For Medicare 2014 New-Tech Add-On Payments

Executive Summary

CMS held its annual new-technology Town Hall February 5, hearing from applicants for a drug-eluting peripheral artery stent, a neurostimulator system for epilepsy seizures, a transcatheter mitral valve repair system and a retinal prosthesis system.

You may also be interested in...

New Products In Brief

Recent approvals and launches include Cook’s Zilver PTX drug-eluting stent for peripheral arterial disease, Medtronic’s Valiant Captivia stent graft system and Cordis’ S.M.A.R.T. Control vascular stent.

FDA Panel: Argus II Artificial Retina’s Benefits Outweigh Risks

Second Sight Medical Products gains FDA panel endorsement for humanitarian device exemption approval of Argus II, which would be the first artificial retina available to restore vision to the blind.

Cook’s Zenith Fenestrated AAA Graft Nets Positive Payment Rulings In Medicare Reg

The firm’s specialized endovascular abdominal aortic aneurysm product was the only device newly awarded a new-technology add-on payment for fiscal 2013, and was moved to a higher-paying procedure category than CMS had previously proposed.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts